- Home
- TCRX vs IFRX Comparison
TCRX vs IFRX Comparison
Compare TCRX & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- IFRX
- Stock Information
- Founded
- TCRX 2018
- IFRX 2007
- Country
- TCRX United States
- IFRX Germany
- Employees
- TCRX N/A
- IFRX N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- TCRX Health Care
- IFRX Health Care
- Exchange
- TCRX Nasdaq
- IFRX Nasdaq
- Market Cap
- TCRX 98.5M
- IFRX 117.8M
- IPO Year
- TCRX 2021
- IFRX 2017
- Fundamental
- Price
- TCRX $1.38
- IFRX $1.02
- Analyst Decision
- TCRX Strong Buy
- IFRX Strong Buy
- Analyst Count
- TCRX 6
- IFRX 2
- Target Price
- TCRX $9.83
- IFRX $9.00
- AVG Volume (30 Days)
- TCRX 442.7K
- IFRX 317.2K
- Earning Date
- TCRX 03-05-2025
- IFRX 03-20-2025
- Dividend Yield
- TCRX N/A
- IFRX N/A
- EPS Growth
- TCRX N/A
- IFRX N/A
- EPS
- TCRX N/A
- IFRX N/A
- Revenue
- TCRX $2,816,000.00
- IFRX $171,642.00
- Revenue This Year
- TCRX $32.21
- IFRX $381.73
- Revenue Next Year
- TCRX $118.35
- IFRX $2,277.23
- P/E Ratio
- TCRX N/A
- IFRX N/A
- Revenue Growth
- TCRX N/A
- IFRX 162.79
- 52 Week Low
- TCRX $1.28
- IFRX $1.02
- 52 Week High
- TCRX $9.69
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- TCRX 31.10
- IFRX 29.28
- Support Level
- TCRX $1.44
- IFRX $1.16
- Resistance Level
- TCRX $1.76
- IFRX $1.42
- Average True Range (ATR)
- TCRX 0.17
- IFRX 0.12
- MACD
- TCRX -0.01
- IFRX 0.02
- Stochastic Oscillator
- TCRX 16.39
- IFRX 0.00
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.